接受根治性放(化)疗的老年头颈部鳞状细胞癌患者中肿瘤浸润免疫细胞与免疫检查点的预后价值
研究纳入63例65岁及以上接受根治性放(化)疗的头颈部鳞状细胞癌患者,采用免疫组化检测治疗前活检组织中CD3、CD4、CD8、PD-L1、TIM3、LAG3、TIGIT、CD96及骨桥蛋白表达,分析其与总生存、无进展生存及局部区域失败的关系,发现LAG3、TIM3及PD-L1肿瘤细胞阳性评分是老年患者有前景的生物标志物,其预后价值主要与局部区域控制相关。
要点
- 上皮内及间质LAG3升高、间质TIM3升高与局部区域失败减少相关。
- 肿瘤PD-L1表达缺失(TPS=0%)与更多局部区域失败相关。
- 上皮内CD3+及CD8+ TIL升高与局部区域失败改善呈趋势,未达统计学显著。
核心结论
- LAG3、TIM3及PD-L1肿瘤细胞阳性评分是接受放(化)疗的老年头颈部鳞状细胞癌患者有前景的生物标志物。
- 考虑到该人群非癌症相关死亡的发生频率,这些生物标志物的预后价值主要与局部区域控制相关。
研究设计与样本
- 研究纳入63例年龄≥65岁、于2010年至2019年间接受根治性放(化)疗、治疗前活检材料充足的头颈部鳞状细胞癌患者。
- 对CD3、CD4、CD8、PD-L1、TIM3、LAG3、TIGIT、CD96及作为免疫衰老相关蛋白的骨桥蛋白进行免疫组化染色。
- 采用Kaplan-Meier法确定总生存和无进展生存,采用Fine-Gray模型进行局部区域失败分析。
主要发现
- 患者年龄与免疫检查点表达无相关性,骨桥蛋白水平与年龄增长相关(r=0.322,p<0.05)。
- 2年总生存、无进展生存和局部区域控制率分别为44%、34%和71%。
- 上皮内LAG3升高(SHR=0.33,p<0.05)、间质LAG3升高(SHR=0.38,p<0.05)及间质TIM3升高(SHR=0.32,p<0.05)与局部区域失败减少对应。
- 肿瘤PD-L1表达缺失(TPS=0%)与更多局部区域失败相关(SHR=0.28,p<0.05)。
- 上皮内CD3+(SHR=0.52,p=0.07)及CD8+(SHR=0.52,p=0.09)TIL升高的老年患者局部区域失败率呈改善趋势。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Tumor-infiltrating lymphocytes (TILs) are associated with locoregional control (LRC) in head-and-neck squamous cell carcinoma (HNSCC) patients undergoing (chemo)radiotherapy. As immunosenescence results in reduced immune activity, the role of TILs in elderly HNSCC patients may differ compared to younger patients, providing a rationale to study the prognostic role of TILs and immune checkpoints (ICs) in this population. MATERIAL AND METHODS: Sixty-three HNSCC patients aged ≥ 65 years undergoing definitive (chemo)radiotherapy between 2010 and 2019 with sufficient material from pre-treatment biopsies were included in the analysis. Immunohistochemical stainings of CD3, CD4, CD8, PD-L1, TIM3, LAG3, TIGIT and CD96, and of osteopontin as an immunosenescence-associated protein were performed. Overall survival (OS) and progression-free survival (PFS) were determined using the Kaplan-Meier method, and Fine-Gray's models were used for locoregional failure (LRF) analyses. RESULTS: While there was no correlation between patient age and IC expression, osteopontin levels correlated with increasing age (r = 0.322, p < 0.05). Two-year OS, PFS, and LRC were 44%, 34%, and 71%, respectively. Increased LAG3 expression, both intraepithelial (SHR = 0.33, p < 0.05) and stromal (SHR = 0.38, p < 0.05), and elevated stromal TIM3 expression (SHR = 0.32, p < 0.05) corresponded with reduced LRFs. Absent tumoral PD-L1 expression (TPS = 0%) was associated with more LRFs (SHR = 0.28, p < 0.05). There was a trend towards improved LRF rates in elderly patients with increased intraepithelial CD3 + (SHR = 0.52, p = 0.07) and CD8 + (SHR = 0.52, p = 0.09) TIL levels. CONCLUSION: LAG3, TIM3 and TPS are promising biomarkers in elderly HNSCC patients receiving (chemo)radiotherapy. Considering the frequency of non-cancer related deaths in this population, the prognostic value of these biomarkers primarily relates to LRC.
引用
- Rühle A, Todorovic J, Spohn SSK, et al. Prognostic value of tumor-infiltrating immune cells and immune checkpoints in elderly head-and-neck squamous cell carcinoma patients undergoing definitive (chemo)radiotherapy. Radiat Oncol. 2022. PMID: 36376922. doi:10.1186/s13014-022-02153-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。